• Mike Adelstein
  • March 23, 2021

Microneedles for vaccine delivery

Microneedles for vaccine delivery

Microneedle-based drug delivery has the potential to be a transformative technology for the delivery of biologics and vaccines. It may provide enhanced therapeutic profiles for therapeutics and vaccines. It allows for the administration of lower levels of drugs to achieve the same therapeutic endpoints. Additionally, microneedles provide an alternative to traditional hypodermic needles. This industry provides a means to overcome one of the biggest barriers to patient compliance and safety for the treatment of chronic diseases and routine vaccination. The variation in the microneedle types could also prove useful in controlling the kinetics of vaccine release. The importance of overcoming stratum corneum barrier is central to the efficient Microneedle-mediate transdermal and intradermal delivery. 1,2

Several new transdermal products mediated by microneedle methods have already been marketed and a few others reach their late-stage development. According to “The Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030” report, more than 70% of the products in development are patches incorporating solid or dissolvable needles, the rest are hollow microneedle arrays that employ the use of a syringe. However, microneedle technologies have not reached their full maturity, yet due to a lack of cost-effective manufacturing technologies. With several new microneedle-based therapeutic product launches by the end of this decade, the report concludes that the overall market for microneedle-based delivery devices will reach annual sales of 485 million units by 2030. https://www.medicaldesignandoutsourcing.com/microneedle-patches-enable-superior-drug-delivery

The images shown here are microneedle molds (diameters of 250 µm to 1 mm) prepared using Potomac’s precision laser etching technologies.

References:

  1. Tuan-Mahmood, T.-M. et al. Microneedles for intradermal and transdermal drug delivery. Eur. J. Pharm. Sci. 50, 623–37 (2013).
  2. Rouphael, N. G. et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet 390, 649–658 (2017).

 

 

Other Posts

From NASA Perseverance Laser Marking on Mars  

To Potomac Laser Marking on Earth Product marking and coding is one of the most successful applications of laser technology. Light engraves a wide variety of substrates quickly and economically and some wavelengths, like those in the ultraviolet, allow for very small micro-marks. Etching a mark right into the surface of a product is a…

  • Potomac Photonics
  • July 28, 2022

​​​​Potomac Accelerates Drug Development

With Organ-on-Chip Technology Innovations In today’s fast-paced world, getting new drugs to market quickly is the holy grail of the pharmaceutical industry. While the urgency of the Coronavirus pandemic was a driver for many drug companies’ commercialization strategies, every firm in the industry needs to generate revenue as quickly as possible in order to recoup…

  • Potomac Photonics
  • July 7, 2022

Potomac Accelerates Shadow Mask 
Manufacturing Speeds

Every day, disruptive technologies allow humans to enter a new world that brings innovations to life. Whether battling climate change by reducing the amount of fossil fuel burning, helping autonomous vehicles navigate roads, guiding man to Mars, or cleaning up toxic waste, technology innovations are the key to solving our world’s problem’s – today and…

  • Potomac Photonics
  • June 28, 2022